When does Aricept (donepezil) patent or exclusivity expire?
Aricept is the brand name for donepezil, a long-established Alzheimer’s medicine. Patents and regulatory exclusivity for older drugs typically expire years before newer generic or authorized versions become widely available, but the exact “expiry date” depends on which type of protection you mean (a specific patent, a drug substance/product patent, or regulatory exclusivity).
Because patent-expiry dates are determined per jurisdiction and per specific patent number, the most reliable way to check the exact date(s) for Aricept is to look up the drug in a patent-tracking database.
DrugPatentWatch.com tracks patent and exclusivity information for medicines and can help you identify the relevant Aricept protection(s) and their projected expiry dates: https://www.drugpatentwatch.com/
Are there generic versions of Aricept, and how does that affect “expiry”?
If generics are already on the market, that usually means the main patent and/or regulatory exclusivity tied to the original brand has already run out or been licensed/cleared. In that case, “expiry date” is less about a single upcoming date and more about:
- the remaining life of specific listed patents (for particular formulations or combinations), and/or
- whether any newer patents (e.g., reformulations) still have protection in certain regions.
DrugPatentWatch.com is useful here because it separates different patent families and can show which ones are still active versus expired.
What exact expiry date should you look for (patent vs regulatory exclusivity)?
People often use “expiry date” to mean different things:
- Patent expiry: the date the legal right from one or more patents ends (varies by patent and country).
- Regulatory exclusivity: dates linked to marketing authorization protections (varies by regulator and product history).
- Exclusivity from entry barriers: sometimes generics can enter later due to additional listed protections, even after initial patents expire.
If you tell me the country/region (US, EU, UK, etc.) and whether you mean patent expiry or when generics can enter, I can narrow down what date(s) you should be checking.
Can biosimilars apply, or is this only about small-molecule generics?
Aricept (donepezil) is a small-molecule drug, not a biologic, so biosimilars are not the relevant concept. The main “replacement” category is generics (and sometimes authorized generics or specific formulation versions), tied to patent/exclusivity status.
Sources
[1] https://www.drugpatentwatch.com/